Keyword: Zelboraf

Roche’s Tecentriq and Cotellic pairing went 0 for 1 in phase 3 melanoma trials—but Friday, they reversed that trend in a Zelboraf combo test.

Thanks to new guidance from England’s drug cost watchdog, Novartis and Roche will be getting some fresh targeted melanoma competition.

Array will challenge pharma giants Novartis and Roche in its rollout of new cancer drugs Braftovi and Mektovi.

Score one for Novartis in its quest to expand its cancer-fighting combo, Tafinlar and Mekinist.

Sun's quarterly U.S. sales dropped 42%, BeiGene offers a public offering of $175 million and the FDA sent a Form 483 to Biocon.

A small drug discovery outfit is challenging one of the world’s largest drugmakers in a cancer drug patent dispute.

With a new green light in Europe in lung cancer, Novartis just took another step in expanding the market for its targeted Tafinlar-plus-Mekinist combination therapy.

Cheered by “extraordinarily high” efficacy in chemo-free combo studies, Roche is powering into late-stage trials with two different melanoma-fighting cocktails based on its brand-new immunotherapy Tecentriq.